Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2021-08-02 Regulatory Filings
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
[기재정정]신규시설투자등
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Legochem Biosciences regarding a 'Correction Report' (정정신고) for a previous 'New Facility Investment' (신규시설투자) disclosure. It details changes to the investment amount and the project completion date due to construction delays. Since this is a specific regulatory disclosure regarding capital expenditure and facility investment updates, it falls under the 'Regulatory Filings' category as it does not fit into more specific categories like M&A or Share Issues.
2021-08-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (specifically due to the resignation of a director). This type of filing is a mandatory regulatory disclosure regarding significant shareholding thresholds and ownership changes, which falls under the 'Major Shareholding Notification' category.
2021-07-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions or changes in ownership status by company directors and executives. According to the provided filing definitions, this corresponds to 'Director's Dealing' (DIRS).
2021-07-23 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision for a third-party capital increase (유상증자결정) by LegoChem Biosciences. In the context of Korean financial regulatory filings (DART), this type of document is a formal announcement of a capital change, specifically a share issuance. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the correct category for announcements regarding new share issues or capital changes.
2021-07-08 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision for a paid-in capital increase (유상증자결정) by LegoChem Biosciences. It details the issuance of new shares, the third-party allocation, pricing, and the purpose of the capital raise. This falls under the category of announcements regarding new share issues or capital changes.
2021-07-08 Korean
[기재정정]투자판단관련주요경영사항(항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from a Korean company (LegoChem Biosciences) regarding a material business event, specifically an amendment to a technology licensing agreement (ADC platform). It details the contract terms, financial milestones, and the nature of the amendment. This falls under the category of general regulatory announcements for material corporate events, which is best classified as RNS (Regulatory Filings) as it does not fit into specific categories like M&A (which usually implies corporate acquisition/merger) or other specialized financial reports.
2021-06-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.